In this edition, we examine the effect of Fintiv on PTAB proceedings dealing with patents asserted in so-called “rocket docket” courts. Next, we provide a brief summary of several recent Federal Circuit cases. We conclude by summarizing recent developments in the Arthrex case at the U.S. Supreme Court and the district court litigation challenging the PTAB’s discretionary denial rules.

Click here to read the newsletter.